Suresh Devineni, MD
Hematology & Oncology · Mankato, MNNPI 1033301858
Payments from drug & device makers
Across 81 payments — averaging $226.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Oncology Corporate, Inc.$3K
- Onmark, Inc.$3K
- Daiichi Sankyo Inc.$3K
- AstraZeneca$2K
- Beigene USA, Inc.$2K
- Gilead$2K
- plus $4K from 31 others
What the payments were for
- Consulting fees$9,87554%
- Speaking & faculty fees$1,4808%
- Travel & lodging$3,39319%
- Food & beverage$3,40219%
- Education$1291%
- Gifts$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Oncology Corporate, Inc. | 7 | $3,266 |
| Onmark, Inc. | 10 | $2,758 |
| Daiichi Sankyo Inc. | 9 | $2,532 |
| AstraZeneca | 6 | $2,138 |
| Beigene USA, Inc. | 1 | $1,925 |
| Gilead(2 entities) | 2 | $1,612 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,365 |
| Beigene, Ltd. | 1 | $525 |
| Pfizer | 2 | $426 |
| Athenex Pharmaceutical Division, LLC | 2 | $325 |
| Novocure GmbH | 1 | $250 |
| Covis Pharma GmbH | 1 | $200 |
| Mckesson Specialty Care Distribution, LLC | 1 | $117 |
| Sanofi | 1 | $105 |
| Cardinal Health 110 LLC | 1 | $100 |
| Genentech USA, Inc. | 2 | $65 |
| Puma Biotechnology, Inc. | 3 | $60 |
| Bristol Myers Squibb | 2 | $55 |
| Acrotech Biopharma Inc. | 4 | $52 |
| Novartis | 3 | $51 |
| Merck | 2 | $50 |
| Astellas Pharma US Inc | 3 | $49 |
| Exelixis Inc. | 1 | $30 |
| Amgen | 1 | $30 |
| Seagen Inc. | 2 | $30 |
| Taiho Oncology, Inc. | 1 | $25 |
| Tesaro, Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $22 |
| GSK | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Caris MPI, Inc. | 1 | $16 |
| Aurobindo Pharma USA, Inc. | 1 | $15 |
| Genmab U.S., Inc. | 1 | $14 |
| Accord Healthcare, Inc. | 1 | $14 |
| AbbVie | 1 | $14 |
| Johnson & Johnson | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,318 in reported general payments places this provider in the 60th percentile of 193 hematology & oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 106 | $1,373,971 |
| XtandiEnzalutamide | 77 | $828,139 |
| IbrancePalbociclib | 43 | $727,563 |
| ImbruvicaIbrutinib | 30 | $558,516 |
| PomalystPomalidomide | 13 | $290,145 |
| CabometyxCabozantinib S-Malate | 12 | $284,683 |
| CalquenceAcalabrutinib Maleate | 13 | $200,127 |
| RevlimidLenalidomide | 11 | $172,333 |
| NubeqaDarolutamide | 22 | $145,079 |
| BrukinsaZanubrutinib | 14 | $142,690 |
| JakafiRuxolitinib Phosphate | 12 | $122,638 |
| Abiraterone Acetate | 16 | $53,208 |
| XareltoRivaroxaban | 48 | $40,259 |
| EliquisApixaban | 53 | $39,633 |
| VenclextaVenetoclax | 12 | $38,255 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $12 | $1,414,230154 claims |
| Astellas Pharma US IncXtandi | $49 | $828,13977 claims |
| PfizerIbrance, Eliquis | $426 | $767,19796 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $12 | $290,14513 claims |
| Exelixis Inc.Cabometyx | $30 | $284,68312 claims |
| AstraZenecaCalquence | $2,138 | $200,12713 claims |
| Bristol Myers SquibbRevlimid | $55 | $172,33311 claims |
| Beigene USA, Inc.Brukinsa | $1,925 | $142,69014 claims |
| AbbVieVenclexta | $14 | $38,25512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 193 hematology & oncology providers in Minnesota.
Other hematology & oncology in Mankato
- Birendra KumarMankato$261K
- Shilpa GuptaMinneapolis$16.3M
- Yucai WangRochester$8.2M
- Daniel AndersonSaint Paul$7.3M
- Timothy LarsonMinneapolis$7.2M
- Yan JiSaint Paul$6.3M
- Manish PatelBloomington$6.2M
- Samith KochuparambilMinneapolis$3.3M
- Thomas AmatrudaFridley$3.3M
- Veronika BachanovaMinneapolis$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.